Executive Leadership
PAUL SHIELDS, PH.D.
CHIEF EXECUTIVE OFFICER
Paul Shields is the CEO of MOD3 Pharma. He is an engineer and a scientist who has spent his career bringing new drugs to life by combining these two fields. As a young scientist with Unigene Laboratories he developed and scaled recombinant manufacturing processes for peptides and proteins. He built the current MOD3 Pharma facility and led a project that resulted in the first approval of a recombinant therapeutic drug through the centralized procedure in Europe. The MOD3 Pharma facility was inspected by numerous agencies from the US and Europe who were interested in what was at the time a new technology for making drugs.
Paul then transitioned the company to the development and manufacture of oral and nasal spray drug products, gaining approval of Fortical nasal spray in the US and launching Peptelligence oral delivery technology. He renovated the facility in 2021 to focus on the development, manufacture and testing of OINDP, leveraging his previous experience with Aptar devices to focus the business on this field and provide end-to-end service to our customers. Paul has a BS in Chemical Engineering from Michigan (Go Blue!) and a PhD from the University of Pennsylvania in Biochemistry.
THOMAS DAGGS, MBA
VICE PRESIDENT, PRODUCT DEVELOPMENT
& QUALITY CONTROL
Thomas Daggs brings over two decades of expertise in biopharmaceutical development with a specialization in drug product Chemistry, Manufacturing, and Controls (CMC). Since joining MOD3 Pharma in 2013, he has played a pivotal role in driving the execution of CMC strategies. Prior to this, he was the Director of Product Development & Quality Control at Unigene Laboratories, where he led analytical and CMC development efforts for solid-dose products.
His career also includes progressively senior roles at Unigene Laboratories and Roche Molecular Systems. Mr. Daggs holds an MBA from Rutgers University and a B.Sc. in Molecular Biology from Montclair State University.
